Mechanism of Action:
Cefpirome binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.
Drug Label Information | Brands:
Brands of Cefpirome in Kenya:
Cefpirome is a fourth-generation cephalosporin antibiotic.
Cefpirome is considered highly active against Gram-negative bacteria, including Pseudomonas aeruginosa, and Gram-positive bacteria.
Cefpirome is primarily indicated in conditions like Bacteremia, Lower respiratory tract infections, Pneumonia, Promyelocytic leukemia, Septicaemia, Severe infections including bacteraemia and septicaemia and infections in neutropenic patients, Skin infections, Soft tissue infections, Urinary tract infection.
DOSAGE AND ADMINISTRATION
1-4 g IV every 12 Hours
Inject over 3-5 min , OR
Intermittent infussion over 20-30 min
- Cefpirome decreases effects of BCG vaccine live by pharmacodynamic antagonism.
- Cefpirome will decrease the level or effect of bazedoxifene / conjugateds estrogens by altering intestinal flora.
- Cefpirome will increase level of digoxin by altering intestinal flora.
- Flucloxacillin: Either increases levels of each other by decreasing renal clearance.
- Cefpirome will increase levels of probenecid by acidic (anionic) drug competition for renal tubular clearance
Skin: Rash, itching and hives.
Gastrointestinal: Nausea, vomiting, abdominal pain and diarrhea.
Liver: Increased level of liver enzymes.
Genitourinary: Kidney inflammation/impairment.
Blood: Decrease in blood counts.
Local: Pain and swelling.
Miscellaneous: Fever and epilepsy.